These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26344609)

  • 21. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
    Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
    J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Sligl WI; Asadi L; Eurich DT; Tjosvold L; Marrie TJ; Majumdar SR
    Crit Care Med; 2014 Feb; 42(2):420-32. PubMed ID: 24158175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
    J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
    Teh B; Grayson ML; Johnson PD; Charles PG
    Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
    Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
    J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia.
    Kolditz M; Halank M; Höffken G
    Treat Respir Med; 2006; 5(6):371-83. PubMed ID: 17154666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
    Amsden GW
    J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
    Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
    Pediatr Pulmonol; 2016 May; 51(5):541-8. PubMed ID: 26367389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination therapy with macrolides for pneumonia].
    Mikamo H; Yamagishi Y
    Jpn J Antibiot; 2011 Jun; 64(3):117-24. PubMed ID: 21861306
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN; Yu VL
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
    Epstein BJ; Gums JG
    Drugs; 2005; 65(14):1949-71. PubMed ID: 16162020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial.
    Figueiredo-Mello C; Naucler P; Negra MD; Levin AS
    Clin Microbiol Infect; 2018 Feb; 24(2):146-151. PubMed ID: 28648859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia.
    Hopkins TM; Juang P; Weaver K; Kollef MH; Betthauser KD
    Clin Ther; 2019 Dec; 41(12):2540-2548. PubMed ID: 31676040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.
    König R; Cao X; Oswald M; Forstner C; Rohde G; Rupp J; Witzenrath M; Welte T; Kolditz M; Pletz M;
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31537702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.
    Falcone M; Russo A; Shindo Y; Farcomeni A; Pieralli F; Cangemi R; Liu J; Xia J; Okumura J; Sano M; Jones C; Vannucchi V; Mancone M; Micek S; Xu F; Violi F; Kollef M
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.